(HER2)2xVγ9

A **bispecific tribody antibody construct** designed to simultaneously target **human epidermal growth factor receptor 2 (HER2)** on tumor cells and activate **Vγ9Vδ2 T cells**, a subset of γδ T cells with anti-tumor activity. This molecule binds HER2 on tumor cells, facilitating recruitment and activation of Vγ9Vδ2 T cells, leading to targeted lysis of HER2-positive cancer cells through immune cell-mediated cytotoxicity. This construct is distinct from monoclonal HER2 antibodies like trastuzumab, as its unique format provides dual binding and immune activation. The approach is primarily being investigated for use in solid tumors overexpressing HER2, such as certain breast and gastric cancers.

Other names

(HER2)2xVγ9(HER2)₂xVγ9HER2xVγ9 tribody